Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Where did “KOLs” come from, and why do they matter?

    September 19, 2024 | Ask Alex, Ask a Medical Writer, Medical Writing 

    Ever wondered where ‘KOLs’ came from and why they matter? Dr Alex Loveday answers those questions in this latest edition of her column.

    - PMLiVE

    The term “Key Opinion Leader” (KOL) originated in mid-20th century sociology, referring to individuals who, due to their expertise, credibility, and social connections, held most influence over opinions and behaviours within their communities. The concept was soon adopted by the pharmaceutical industry, recognising the strategic advantage of leveraging trusted experts to shape perceptions and accelerate the adoption of new therapies.

    Having gained traction within pharma in the 1970s, by late 1980s, KOL engagement had already become pivotal to the industry, leveraged to advance both clinical practice and public health strategies. For example, during the height of the HIV/AIDS crisis, pharmaceutical companies heavily relied on KOLs to inspire new treatment paradigms. Influential physicians, such as Dr. David Ho, were central to educating healthcare providers about the emerging antiretroviral therapies and shaping public health responses. Today, KOLs are integral to the success of pharma strategic communications, their influence accounting for 60-70% of new therapy adoptions and driving market penetration.

    Bridging the gap between scientific research and clinical practice, KOLs provide not only validation of a product’s scientific merit but also actionable insights on its integration into clinical settings. Whether through peer-reviewed publications, advisory boards, or speaker programs, they play a critical role in driving informed and impactful decision-making across the healthcare ecosystem while guiding product strategy. KOL voices amplify the reach and impact of a brand’s messaging, lending it vital credibility and driving engagement within the healthcare community. Conversely, strategic KOL partnerships help pharma companies gain deeper insight into unmet medical needs and inform future research priorities to better serve the public and advance healthcare.

    Going forward, strategic KOL engagement will quite certainly remain key in both amplifying current communications and anticipating future market trends. As healthcare becomes increasingly personalised and data-driven, KOL partnerships stand to become a forward-looking strategy that keeps brands agile, relevant and connected to the evolving landscape of medicine.

    This content was provided by Mednet